Modulation of GvHD by suicide-gene transduced donor T lymphocytes

Clinical applications in mismatched transplantation

Fabio Ciceri, C. Bonini, C. Gallo-Stampino, C. Bordignon

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

In allogeneic hematopoietic cell transplantation (allo-HCT), donor lymphocytes play a central therapeutic role in both GvL and immune reconstitution. However the full exploitation of these therapeutic properties is limited by the occurrence of GvHD. Diffierent strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. The genetic engineering of donor lymphocytes with the herpes simplex virus-thymidine kinase (HSV-TK) suicide gene confers the ability to modulate GvHD by in vivo ganciclovir-induced elimination of the transduced cells. The suicide-gene strategy has applications in both donor lymphocyte infusion (DLI) for disease relapse and in add-back infusions after T-cell depleted allo-HCT. TK cell DLI resulted in anti-tumor activity in a relevant proportion of treated patients. Haplo-identical stem cell transplantation (haplo-HCT) is a promising therapeutic option for patients with high risk hematologic malignancies lacking an HLA-matched donor. However, the profound T-cell depletion required to overcome the risk of lethal GvHD has been associated with a marked delayed T-cell recovery with a prolonged risk of post-transplant viral, fungal and other opportunistic infections. TK cell add-backs efficiently promote early immune reconstitution after haplo-HCT and prevent disease relapse providing a unique tool for the control of GvHD. The genetic manipulation of donor lymphocytes with a suicide gene is a promising strategy to increase feasibility and safety of allo-HCT.

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalCytotherapy
Volume7
Issue number2
DOIs
Publication statusPublished - 2005

Fingerprint

Transgenic Suicide Genes
Transplantation
Tissue Donors
T-Lymphocytes
Lymphocytes
Cell Transplantation
Suicide
Genes
Recurrence
Ganciclovir
Aptitude
Genetic Engineering
Thymidine Kinase
Opportunistic Infections
Stem Cell Transplantation
Hematologic Neoplasms
Simplexvirus
Therapeutics

Keywords

  • Allogeneic transplantation
  • Gene therapy
  • HSV-TK

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Modulation of GvHD by suicide-gene transduced donor T lymphocytes : Clinical applications in mismatched transplantation. / Ciceri, Fabio; Bonini, C.; Gallo-Stampino, C.; Bordignon, C.

In: Cytotherapy, Vol. 7, No. 2, 2005, p. 144-149.

Research output: Contribution to journalArticle

@article{ac89cac2af104cc5b2065b015274a541,
title = "Modulation of GvHD by suicide-gene transduced donor T lymphocytes: Clinical applications in mismatched transplantation",
abstract = "In allogeneic hematopoietic cell transplantation (allo-HCT), donor lymphocytes play a central therapeutic role in both GvL and immune reconstitution. However the full exploitation of these therapeutic properties is limited by the occurrence of GvHD. Diffierent strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. The genetic engineering of donor lymphocytes with the herpes simplex virus-thymidine kinase (HSV-TK) suicide gene confers the ability to modulate GvHD by in vivo ganciclovir-induced elimination of the transduced cells. The suicide-gene strategy has applications in both donor lymphocyte infusion (DLI) for disease relapse and in add-back infusions after T-cell depleted allo-HCT. TK cell DLI resulted in anti-tumor activity in a relevant proportion of treated patients. Haplo-identical stem cell transplantation (haplo-HCT) is a promising therapeutic option for patients with high risk hematologic malignancies lacking an HLA-matched donor. However, the profound T-cell depletion required to overcome the risk of lethal GvHD has been associated with a marked delayed T-cell recovery with a prolonged risk of post-transplant viral, fungal and other opportunistic infections. TK cell add-backs efficiently promote early immune reconstitution after haplo-HCT and prevent disease relapse providing a unique tool for the control of GvHD. The genetic manipulation of donor lymphocytes with a suicide gene is a promising strategy to increase feasibility and safety of allo-HCT.",
keywords = "Allogeneic transplantation, Gene therapy, HSV-TK",
author = "Fabio Ciceri and C. Bonini and C. Gallo-Stampino and C. Bordignon",
year = "2005",
doi = "10.1080/14653240510018136",
language = "English",
volume = "7",
pages = "144--149",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Modulation of GvHD by suicide-gene transduced donor T lymphocytes

T2 - Clinical applications in mismatched transplantation

AU - Ciceri, Fabio

AU - Bonini, C.

AU - Gallo-Stampino, C.

AU - Bordignon, C.

PY - 2005

Y1 - 2005

N2 - In allogeneic hematopoietic cell transplantation (allo-HCT), donor lymphocytes play a central therapeutic role in both GvL and immune reconstitution. However the full exploitation of these therapeutic properties is limited by the occurrence of GvHD. Diffierent strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. The genetic engineering of donor lymphocytes with the herpes simplex virus-thymidine kinase (HSV-TK) suicide gene confers the ability to modulate GvHD by in vivo ganciclovir-induced elimination of the transduced cells. The suicide-gene strategy has applications in both donor lymphocyte infusion (DLI) for disease relapse and in add-back infusions after T-cell depleted allo-HCT. TK cell DLI resulted in anti-tumor activity in a relevant proportion of treated patients. Haplo-identical stem cell transplantation (haplo-HCT) is a promising therapeutic option for patients with high risk hematologic malignancies lacking an HLA-matched donor. However, the profound T-cell depletion required to overcome the risk of lethal GvHD has been associated with a marked delayed T-cell recovery with a prolonged risk of post-transplant viral, fungal and other opportunistic infections. TK cell add-backs efficiently promote early immune reconstitution after haplo-HCT and prevent disease relapse providing a unique tool for the control of GvHD. The genetic manipulation of donor lymphocytes with a suicide gene is a promising strategy to increase feasibility and safety of allo-HCT.

AB - In allogeneic hematopoietic cell transplantation (allo-HCT), donor lymphocytes play a central therapeutic role in both GvL and immune reconstitution. However the full exploitation of these therapeutic properties is limited by the occurrence of GvHD. Diffierent strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. The genetic engineering of donor lymphocytes with the herpes simplex virus-thymidine kinase (HSV-TK) suicide gene confers the ability to modulate GvHD by in vivo ganciclovir-induced elimination of the transduced cells. The suicide-gene strategy has applications in both donor lymphocyte infusion (DLI) for disease relapse and in add-back infusions after T-cell depleted allo-HCT. TK cell DLI resulted in anti-tumor activity in a relevant proportion of treated patients. Haplo-identical stem cell transplantation (haplo-HCT) is a promising therapeutic option for patients with high risk hematologic malignancies lacking an HLA-matched donor. However, the profound T-cell depletion required to overcome the risk of lethal GvHD has been associated with a marked delayed T-cell recovery with a prolonged risk of post-transplant viral, fungal and other opportunistic infections. TK cell add-backs efficiently promote early immune reconstitution after haplo-HCT and prevent disease relapse providing a unique tool for the control of GvHD. The genetic manipulation of donor lymphocytes with a suicide gene is a promising strategy to increase feasibility and safety of allo-HCT.

KW - Allogeneic transplantation

KW - Gene therapy

KW - HSV-TK

UR - http://www.scopus.com/inward/record.url?scp=21044453633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044453633&partnerID=8YFLogxK

U2 - 10.1080/14653240510018136

DO - 10.1080/14653240510018136

M3 - Article

VL - 7

SP - 144

EP - 149

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 2

ER -